ArticleDialogues in clinical neuroscience2002
Pathophysiology of depression and mechanisms of treatment.
Article in Dialogues in clinical neuroscience, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association between prenatal maternal anxiety and/or stress and offspring's cognitive functioning: A meta-analysis.Child development · 2023Pooled it
- Altered Composition of Gut Microbiota in Depression: A Systematic Review.Frontiers in psychiatry · 2020Pooled it
- MicroRNAs expressed in depression and their associated pathways: A systematic review and a bioinformatics analysis.Journal of chemical neuroanatomy · 2019Pooled it
- Postoperative but not preoperative depression is associated with cognitive impairment after cardiac surgery: exploratory analysis of data from a randomized trial.BMC anesthesiology · 2022Trial
- Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease After Developing Depression: A Population-Based Cohort Study.Journal of Korean medical science · 2026Article
- Feasibility and Tolerability ofAnnals of neurosciences · 2026Article
- Re-Examination of Inflammation in Major Depressive Disorder: Bridging Systemic and Neuroinflammatory Insights.Biomolecules · 2025Review
- Towards Objective Major Depressive Disorder Detection: a Systematic Review and Meta-Analysis of Diagnostic Biomarkers.The Psychiatric quarterly · 2025Review
- The Pathogenesis and Medical Treatment of Depression: Opportunity and Challenge.Neurology international · 2025Review
- The Potential of Selected Plants and Their Biologically Active Molecules in the Treatment of Depression and Anxiety Disorders.International journal of molecular sciences · 2025Review
- Beyond weight loss: exploring the neurological ramifications of altered gut microbiota post-bariatric surgery.Journal of translational medicine · 2025Review
- Longitudinal Effects of Lifetime Caffeine Consumption on Levels of Depression, Anxiety, and Stress: A Comprehensive Review.Current nutrition reports · 2025Review
- New perspectives on microbiome-dependent gut-brain pathways for the treatment of depression with gastrointestinal symptoms: from bench to bedside.Journal of Zhejiang University. Science. B · 2025Review
- Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions.American journal of clinical dermatology · 2025Review
- Deficiency of vitamin D is associated with antenatal depression: a cross-sectional study.Trends in psychiatry and psychotherapy · 2025Article
- Randomized controlled trial to assess medication adherence and health-related quality of life through a collaborative pharmacist-psychiatrist approach to patient education in patients with depression in India.Frontiers in psychiatry · 2025Article
- Lithium in Drinking Water and its Potential Impact on Mental Health: A Review.Current medicinal chemistry · 2025Review
- Using the Complex Network Model to Associate Nutritional, Psychological, and Physical Parameters and Aspects of Sleep with Depression Symptoms.Journal of clinical medicine · 2024Article
- Integrated Long Noncoding RNA and Messenger RNA Expression Analysis Identifies Molecules Specifically Associated With Resiliency and Susceptibility to Depression and Antidepressant Response.Biological psychiatry global open science · 2024Article
- Gepirone: A New Extended-Release Oral Selective Serotonin Receptor Agonist for Major Depressive Disorder.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depression is a serious disorder of enormous sociological and clinical relevance. The discovery of antidepressant drugs in the 1950s led to the first biochemical hypothesis of depression, which suggested that an impairment in central monoaminergic function was the major lesion underlying the disorder. Basic research in all fields of neuroscience (including genetics) and the discovery of new antidepressant drugs have revolutionized our understanding of the mechanisms underlying depression and drug action. There is no doubt that the monoaminergic system is one of the cornerstones of these mechanisms, but multiple interactions with other brain systems and the regulation of central nervous system function must also be taken into account In spite of all the progress achieved so far, we must be aware that many open questions remain to be resolved in the future.
Indexed as
Identifiers
22033824PMC3181668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.